In a diabetic patient whose HbA1c remains 8.9% despite maximal metformin therapy, what glucose‑lowering medication should be added next?

Add a GLP-1 Receptor Agonist or SGLT2 Inhibitor Next

For your patient with an A1c of 8.9% on maximal metformin, you should add either a GLP-1 receptor agonist or an SGLT2 inhibitor as the next medication, with the specific choice determined by the presence of cardiovascular disease, chronic kidney disease, or heart failure. 1

Decision Algorithm Based on Comorbidities

If Your Patient Has Any of These Conditions:

Cardiovascular Disease (CVD):

• Add a GLP-1 RA with proven CVD benefit (e.g., liraglutide, semaglutide, dulaglutide) 1
• GLP-1 RAs are preferred for ASCVD and show superior MACE reduction 2
• Expected A1c reduction: 1.0-2.0% 1

Chronic Kidney Disease (CKD):

• Add an SGLT2 inhibitor if eGFR >20 mL/min/1.73 m² 1
• SGLT2 inhibitors have the strongest evidence for preventing CKD progression, especially with significant albuminuria (UACR >300 mg/g) 2
• Alternative: GLP-1 RA (effective regardless of kidney function) 1

Heart Failure (especially HFrEF):

• Add an SGLT2 inhibitor 2
• SGLT2 inhibitors reduce hospitalization for heart failure, MACE, and CV death 2

If Your Patient Has Multiple CV Risk Factors But No Established Disease:

Either GLP-1 RA or SGLT2 inhibitor is appropriate 1

• Both classes are recommended independent of A1c level 1
• Consider patient preference regarding injection frequency (GLP-1 RAs) vs. oral medication (SGLT2 inhibitors)
• Expected A1c reduction: 0.7-1.0% for SGLT2 inhibitors; 1.0-2.0% for GLP-1 RAs 1

If Your Patient Has No CVD/CKD/HF:

GLP-1 RA is the preferred choice for this degree of A1c elevation (8.9%)

• More potent glucose-lowering than SGLT2 inhibitors 1, 3
• Long-acting GLP-1 RAs (liraglutide, semaglutide, exenatide LAR) provide greater A1c reduction than short-acting agents 3
• Weight loss benefit: typically 2-4 kg 3
• Low hypoglycemia risk 3

Why Not Other Options?

DPP-4 Inhibitors: Less effective than GLP-1 RAs (similar A1c reduction to short-acting GLP-1 RAs but inferior to long-acting formulations), no cardiovascular or renal benefits 1, 3

Sulfonylureas: Increase hypoglycemia and weight gain risk; modern guidelines deprioritize these agents when GLP-1 RAs and SGLT2 inhibitors are available 1

Basal Insulin: Reserve for when even greater glucose reduction is needed or if GLP-1 RA/SGLT2 inhibitor therapy proves insufficient 1

Critical Implementation Points

• Do not delay treatment intensification – therapeutic inertia worsens outcomes 1
• Continue metformin when adding the second agent 4 – switching rather than adding provides no benefit and may worsen control 4
• Reassess at 3-6 months with repeat A1c to confirm response 1
• If inadequate response persists, add a third agent from the other preferred class (if started GLP-1 RA, add SGLT2 inhibitor, or vice versa) rather than switching 4

Common Pitfalls to Avoid

Never combine GLP-1 RA with DPP-4 inhibitor – no additional glucose-lowering benefit 1

Don't wait too long to assess response – if A1c remains elevated at 6 months, add another agent rather than continuing unchanged 4

For SGLT2 inhibitors: Screen for genital mycotic infection risk and counsel on foot care if amputation risk factors present 2

For GLP-1 RAs: Expect transient nausea (counsel patients this typically resolves); titrate dose gradually to minimize GI side effects 3